Medtronic plc Stock Price and Value Analysis

Medtronic plc (NYSE:MDT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: MDT (NYSE)
  • Current price: $100.72
  • Sector: Unknown
  • Industry: Unknown
  • Dividend yield: 2.79%

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Medtronic plc to reach your target.

Target type

MDT Free Cash Flow Trend

Free Cash Flow trendline for MDT
Free Cash Flow trendline for Medtronic plc
CSV

Based on historical returns, we believe that Medtronic plc can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantages
  • This company is very stable.
  • This company has stable growth.
  • This company has a high dividend yield.
  • This stock is on sale.
  • This company is making money at a modest rate.

Inside the MDT Numbers

MDT Price
(Medtronic plc stock price per share)
$100.72
[?] MDT Fair Price
(based on intrinsic value)
$108.80
[?] MDT Safety Price (based on a variable margin of safety) $87.04
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 69% higher than other Unknown stocks
[?] PE Ratio versus Industry 138% higher than other Unknown stocks
[?] Cash Yield 4.44%
[?] Free Cash Flow Jitter 12%
[?] Dividend Yield 2.79% (tax impact)
Shares Shorted 22,952,253

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 22,952,253 shares shorted. With 1,276,643,571 shares available for purchase and an average trading volume over the past 10 trading days of 6,936,340, it would take at least 3.3 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2013 1613103
2014 1613103
2015 1613103
2016 1613103
2017 1613103
2018 1613103
2019 1613103
2020 1613103
2021 1613103
2022 1613103
2023 1613103
2024 1613103
2025 1613103
2026 1613103

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 14 fiscal years from 2013 to 2026 with positive net income, operating cash flow totaled $86612.0 million against net income of $54839.0 million, or 1.58 times.

In 2026, operating cash flow was 1.53 times net income, compared with 1.61 times for the earliest three years (2013 to 2015).

In 2026, capital expenditures were $1904.0 million, 26.0% of operating cash flow of $7330.0 million, which leaves an estimated $5426.0 million after capex. Across the 14 years with reported capex, it averaged 19.2% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2013 3467.0 4942.0 457.0 1.43
2014 3065.0 4959.0 396.0 1.62
2015 2675.0 4902.0 571.0 1.83
2016 3538.0 5218.0 1046.0 1.47
2017 4028.0 6880.0 1254.0 1.71
2018 3104.0 4684.0 1068.0 1.51
2019 4631.0 7007.0 1134.0 1.51
2020 4789.0 7234.0 1213.0 1.51
2021 3606.0 6240.0 1355.0 1.73
2022 5039.0 7346.0 1368.0 1.46
2023 3758.0 6039.0 1459.0 1.61
2024 3676.0 6787.0 1587.0 1.85
2025 4662.0 7044.0 1859.0 1.51
2026 4801.0 7330.0 1904.0 1.53

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2017 to 2026 with dividend or share repurchase facts, estimated free cash flow totaled $54526.0 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $31470.0 million, 57.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 10 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $20167.0 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2026, dividends and cash spent repurchasing shares together were $4674.0 million, 82.1% of estimated free cash flow of $5694.6 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2017 6135.2 2376.0 3544.0 5920.0 96.5%
2018 3817.0 2494.0 2171.0 4665.0 122.2%
2019 5992.4 2693.0 2877.0 5570.0 93.0%
2020 6091.0 2894.0 1326.0 4220.0 69.3%
2021 5035.2 3120.0 652.0 3772.0 74.9%
2022 6118.4 3383.0 2544.0 5927.0 96.9%
2023 4733.2 3616.0 645.0 4261.0 90.0%
2024 5390.6 3666.0 2138.0 5804.0 107.7%
2025 5518.4 3589.0 3235.0 6824.0 123.7%
2026 5694.6 3639.0 1035.0 4674.0 82.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $16590.0 million in 2013 and $36364.0 million in 2026, a compound annual growth rate of 6.2% over 13 years.

Revenue rose 8.4% from 2025 to 2026.

Our estimated free cash flow was $5694.6 million in 2026, 15.7% of revenue. In 2013 the estimated margin was 27.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2013 16590.0 4485.0 27.0%
2014 17005.0 4532.5 26.7%
2015 20261.0 4427.3 21.9%
2016 28833.0 4600.5 16.0%
2017 29710.0 6135.2 20.7%
2018 29953.0 3817.0 12.7%
2019 30557.0 5992.4 19.6%
2020 28913.0 6091.0 21.1%
2021 30117.0 5035.2 16.7%
2022 31686.0 6118.4 19.3%
2023 31227.0 4733.2 15.2%
2024 32364.0 5390.6 16.7%
2025 33537.0 5518.4 16.5%
2026 36364.0 5694.6 15.7%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2026, cash and equivalents were $1949.0 million against total liabilities of $42956.0 million, or 4.5% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 46.2% of total assets in 2026, compared with 48.8% in 2014, a decrease of 2.6 percentage points.

Stockholders equity was $50072.0 million in 2026, compared with $19443.0 million in 2014, a rise of 157.5%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 7.2% in 2026. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2014 37943.0 1403.0 18500.0 19443.0
2015 106685.0 4843.0 53541.0 53230.0
2016 99644.0 2876.0 47667.0 52063.0
2017 99857.0 4967.0 49527.0 50330.0
2018 91393.0 3669.0 40571.0 50822.0
2019 89694.0 4393.0 39482.0 50212.0
2020 90689.0 4140.0 39817.0 50872.0
2021 93083.0 3593.0 41481.0 51602.0
2022 90981.0 3714.0 38259.0 52722.0
2023 90948.0 1543.0 39283.0 51665.0
2024 89981.0 1284.0 39561.0 50420.0
2025 91680.0 2218.0 43424.0 48256.0
2026 93028.0 1949.0 42956.0 50072.0

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $100.72, our model's value equals that price if free cash flow grows an average of 2.9 percent a year over the 10 projection years. Our model assumes 4.5 percent a year for this stock, so the price implies growth of 2.9 percent, which is below the 4.5 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $5,715.0 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $80.58 -2.5%
Current price $100.72 2.9%
20 percent above the current price $120.86 6.7%
Our model (stored fair price) $108.80 4.5%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 14 fiscal years we have for Medtronic plc under its current SEC filer.

Medtronic plc at $100.72 lies between its safe value ($87.04) and its fair value ($108.80).

Average free cash flow over the last three years of data was $5534.5 million, and across the first three years it was $4481.6 million; over the period it rose.

Year-to-year variability in free cash flow is fairly steady, measured at 12%.

The dividend yield for Medtronic plc is 2.79%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1613103.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2026
Price and market data last refreshed
2026-11-18
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: MDT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in MDT

Does Medtronic plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: MDT

This example shows how we apply the Trendshare checklist to MDT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 100.72
    • Market cap: $129B
    • EPS: 4.07
  2. Step 2 — Valuation checks

    • P/E: 24.747
    • FCF yield: 4.4%
    • Date checked: Nov 18, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.